Pfizer Presents Positive 26-Week Data For PF-05280586, A Potential Biosimilar To Rituximab, At The American Society Of Hematology Annual Meeting
________________________________ i Rituximab is marketed in the U.S. under the brand name Rituxan? and marketed in the E.U. and other regions under the brand name MabThera?. Rituxan? and MabThera? are registered trademarks of Genentech, Inc. 1 Sharman, J et al. A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera?) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL). ASH 2018. Available at https://ash.confex.com/ash/2018/webprogram/Paper111248.html. Accessed November 2018. 2 EMA Product Information for RETACRIT. Available at: https://www.ema.europa.eu/medicines/human/EPAR/retacrit. Accessed November 2018. 3 FDA Prescribing Information for RITUXAN. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103705s5367s5388lbl.pdf. Accessed November 2018. 4 EMA Product Information for MABTHERA. Available at: https://www.ema.europa.eu/medicines/human/EPAR/mabthera#product-information-section. Accessed November 2018.